Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Weekly Buzzing Stocks by Billy Kawasaki and The Panic-Proof Portfolio (Stockchase Research) commented about whether ATD-T, HBM-T, NVDA-Q, CNR-T, TSLA-Q, LLY-N, GM-N are stocks to buy or sell.
- Page 1/3
- Next Page
- General Motors Corporation (GM-N)
- Eli Lilly & Co. (LLY-N)
- NVIDIA Corporation (NVDA-Q)
- Tesla Inc (TSLA-Q)
- Alibaba Group Holding (BABA-N)
- Microsoft Corp (MSFT-Q)
- Main Street Capital Corp. (MAIN-N)
- Apple Inc (AAPL-Q)
- Broadcom (AVGO-Q)
- Procter & Gamble (PG-N)
- Invesco QQQ Trust Series 1 (QQQ-Q)
- Hecla Mining Co (HL-N)
- Interactive Brokers Group, Inc. (IBKR-Q)
- Automatic Data Processing (ADP-Q)
- Rocket Lab USA (RKLB-Q)
General Motors Company designs, builds, and sells trucks, crossovers, cars, and automobile parts and accessories in North America, the Asia Pacific, the Middle East, Africa, South America, the United States, and China. The company operates through GM North America, GM International, Cruise, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Holden, Baojun, and Wuling brand names. The company also sells trucks, crossovers, cars, and purpose-built vehicles to dealers for consumer retail sales, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers safety and security services for retail and fleet customers, including automatic crash response, emergency services, roadside assistance, crisis assist, stolen vehicle assistance, and turn-by-turn navigation; and connected services comprising mobile applications for owners to remotely control their vehicles and electric vehicle owners to locate charging stations, on-demand vehicle diagnostics, smart driver, marketplace in-vehicle commerce, in-vehicle voice, voice assistant, navigation and app ecosystem, connected navigation, SiriusXM with 360L, and 4G LTE wireless connectivity, as well as develops and commercializes autonomous vehicle technology. Further, the company provides automotive financing and insurance services; and software-enabled services and subscriptions. General Motors Company was founded in 1908 and is headquartered in Detroit, Michigan. Social media mentions are up 650% in the past 24h.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Social media mentions are up 3000% in the past 24h.
Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. It operates in two segments, Automotive, and Energy Generation and Storage. The Automotive segment offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty after-sales vehicle, used vehicles, retail merchandise, and vehicle insurance services. This segment also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. The Energy Generation and Storage segment engages in the design, manufacture, installation, sale, and leasing of solar energy generation and energy storage products, and related services to residential, commercial, and industrial customers and utilities through its website, stores, and galleries, as well as through a network of channel partners; and provision of service and repairs to its energy product customers, including under warranty, as well as various financing options to its solar customers. The company was formerly known as Tesla Motors, Inc. and changed its name to Tesla, Inc. in February 2017. Tesla, Inc. was incorporated in 2003 and is headquartered in Austin, Texas. Social media mentions are up 247% in the past 24h.
CNR controls 19,500 miles of rail in Canada and the US and is intricate to the economy. EPS grew 5% over the year in a trying market, now analysts expect double-digit annual growth over the next 5 years. It trades at 18x earnings and supports 27% ROE. We like that cash reserves are growing, while debt is aggressively retired and shares bought back. We recommend setting a stop-loss at $141, looking to achieve $181 -- upside potential of 17%. Yield 2.0%
(Analysts’ price target is $180.71)The company is simply the most important chip manufacturer in the AI race. Its newest chip in development is in huge demand. You have to get by the expensive valuation -- 56x earnings and 50x book; however, it supports a ROE of 123%. We like that cash reserves are growing sharply as the company aggressively buys back shares and retires debt. We recommend setting a stop-loss at $95, looking to achieve $148 -- upside potential of 21%. Yield 0.2%
(Analysts’ price target is $148.13)HBM focuses on copper, gold and zinc production with primary production in Peru and Canada. It has benefited from both rising production and prices. Management has used the growing free cash flow to de-lever its balance sheet, while growing cash reserves. We recommend setting a stop-loss at $9, looking to achieve $16 -- upside potential of 28%. Yield 0.1%
(Analysts’ price target is $15.82)Our PAST TOP PICK with ATD has triggered its stop at $74. To remain disciplined, we recommend covering the position at this time. When combined with previous guidance, this will result in a net investment gain of 18%.
Geopolitical conflict certainly adds volatility and, generally, October isn't the strongest month for investing. Factor those two things in with other economic data such as US non-farm payrolls tomorrow. He wouldn't be surprised if the runup over the last year takes a bit of a pause for maybe a month. Not expecting major declines, but can anticipate market trading sideways to slightly down.
Then late October/early November, the bull market will continue its run through the next 6-8 months or so.
That's it primarily. His view is that economic data will continue to come in weaker. A number of data points have been revised downward over the past few quarters. That will continue, sees further weakness in the economy. We're in one of those funny cycles now where bad economic news somehow means good news in the stock market. Lowering inflation expectations and interest rates will propel markets forward. He is starting to worry about late 2025 and into 2026.
But for the next 10 months or so, you might want to be invested a little more aggressively, to take advantage of what should be a continuation of market strength.
For the last 6 months, he's leaned into the AI, tech-driven themes. That said, there's always going to be movement between growth and value. At different times, value and interest-rate sensitives will have their day in the sun.
His overall view is that growth-focused securities will primarily drive the market going forward. Any short-term pullback on core names such as NVDA or mega-cap tech is a buying opportunity. Doesn't mean you can't have other things in your portfolio, as diversification is always an important factor.
But if he was choosing one sector to ride for the next 6 months or so, it would definitely be the more tech-focused sector.
An income play, using leverage and covered calls. Always be cautious using leverage. Leverage to the upside is great, to the downside it hurts a bit more. Income generated is very strong.
These strategies can work very well if you're less concerned about capital appreciation and more about income. Geared to work well in a sideways or down market. These products are popular, but he doesn't use them. Know what you're getting into.
There's another Hamilton ETF that isn't as levered. Its distribution is about half of HCAL, but performance has been significantly better. In an upward market, you want more exposure to the underlying bank stocks.
Recent sale of MLSE will generate significant cash windfall. Comes at a good time, with concerns about debt load. Debt rating was cut. Traditionally owned for the dividend, so a cut would be a last resort. That said, you still need strong cashflows to pay that dividend while servicing your debt.
Not super-high on his list of Canadian stocks to own, but he does understand income needs. Rate cuts should propel stock forward. Not a terrible stock, but he'd look elsewhere.
